Tuberculosis & MDR-TB Treatment in India 2026: Costs, Regimens & Outcomes for International Patients
Tuberculosis remains the world's deadliest infectious disease, killing 1.3 million people annually. India carries the highest TB burden of any nation, but that same scale has driven the country to develop world-class TB elimination infrastructure — modern diagnostics, WHO-endorsed drug regimens, and specialist pulmonologists with unmatched treatment volume. For African patients with drug-resistant TB who cannot access adequate care at home, India offers a genuine lifeline.
TL;DR: MDR-TB treatment in India costs USD 3,000–8,000 for the full course. The BPaL (Bedaquiline, Pretomanid, Linezolid) regimen achieves 89% success in 6 months. Isolation protocols meet WHO standards. India's generic pharmaceutical industry makes new TB drugs affordable where they are USD 50,000+ in Western countries.
India's TB Elimination Mission
India launched its National TB Elimination Programme with a 2025 target (later revised to 2030) to reduce TB incidence to under 10 per 100,000. This mission has produced substantial infrastructure investment: GeneXpert machines in thousands of laboratories, drug susceptibility testing (DST) capacity in every major city, digital treatment adherence monitoring systems, and dedicated MDR-TB centres with negative-pressure isolation facilities.
For international patients, this means India has the diagnostic and therapeutic infrastructure to handle even the most complex TB cases — XDR-TB, bedaquiline-resistant strains, TB-HIV co-infection, and paediatric TB — with protocols that match or exceed global standards.
Understanding TB Drug Resistance Classification
Before discussing treatment, it is important to understand the resistance classification system:
| Classification | Definition | Treatment Duration |
|---|---|---|
| Drug-Sensitive (DS-TB) | Responds to standard first-line drugs | 6 months |
| MDR-TB | Resistant to isoniazid + rifampicin | 6–18 months |
| Pre-XDR-TB | MDR + resistant to fluoroquinolones | 6–18 months |
| XDR-TB | MDR + resistant to fluoroquinolones + bedaquiline/linezolid | 6–24 months |
The BPaL Regimen: India's Game-Changer
The BPaL regimen (Bedaquiline, Pretomanid, Linezolid) represents the most significant advance in TB treatment in decades. WHO recommended it in 2022 based on the ZeNix and TB-PRACTECAL trials showing 89% treatment success for XDR-TB in just 6 months — compared to the historical 40–60% success with older 18–24 month regimens.
India adopted BPaL for MDR-TB and XDR-TB treatment in accredited TB centres. The drugs are available as generics through India's pharmaceutical manufacturing base at a fraction of brand-name costs. Bedaquiline, which costs USD 30,000 for a 6-month course in Western markets, is available in India for under USD 1,500.
Treatment Protocols at Indian TB Centres
Pre-Treatment Evaluation
Before starting MDR-TB treatment, Indian centres conduct comprehensive evaluation:
- Chest X-ray and CT scan: Extent of disease, cavities, complications
- Sputum culture and DST: Comprehensive drug susceptibility testing including second-line drugs
- GeneXpert Ultra: Rapid molecular detection of rifampicin and isoniazid resistance
- Line probe assay (LPA): Fluoroquinolone and second-line injectable resistance
- Whole genome sequencing (WGS): At specialist centres for complex resistance patterns
- HIV testing and CD4 count: TB-HIV co-infection significantly affects treatment selection
- Cardiac evaluation (ECG): QT interval monitoring essential for bedaquiline and clofazimine
Isolation Protocols
Indian hospitals accredited for TB care maintain rigorous infection control:
Negative-pressure isolation rooms with at least 12 air changes per hour prevent TB transmission to other patients and staff. HEPA filtration is standard in TB wards. All staff wear N95 respirators when entering isolation rooms. UV germicidal irradiation is used in corridors and waiting areas.
International patients receive private negative-pressure single rooms. Duration of isolation depends on sputum smear conversion — most patients become smear-negative within 4 to 8 weeks of effective treatment.
MDR-TB Treatment Regimens
BPaL-M regimen (preferred for MDR/XDR-TB):
Bedaquiline (400mg daily for 2 weeks, then 200mg 3× weekly) + Pretomanid (200mg daily) + Linezolid (600mg daily) ± Moxifloxacin. Duration: 6 months. Success rate: 89%.
Longer BPaL regimens: For certain resistance profiles or treatment-failed patients, BPaL is extended to 9 months with enhanced monitoring.
Older 18–24 month regimens are still used when bedaquiline or pretomanid resistance is confirmed, combining agents from WHO Group A, B, and C drugs.
Costs: India vs Global Comparisons
| Treatment Component | India (USD) | USA (USD) | UK (GBP) |
|---|---|---|---|
| BPaL drugs (6-month course) | 1,500–2,500 | 50,000–80,000 | 30,000–50,000 |
| Hospitalisation (2 months) | 2,000–4,000 | 40,000–80,000 | 25,000–50,000 |
| DST and monitoring labs | 500–1,000 | 3,000–6,000 | 2,000–4,000 |
| CT chest and imaging | 200–400 | 1,500–3,000 | 800–1,500 |
| Full MDR-TB treatment package | 3,000–8,000 | 100,000+ | 60,000+ |
Sources: WHO Global TB Report 2024; Arodya hospital quotes 2025.
Completing Treatment: India vs Home Country Hybrid
Many international MDR-TB patients adopt a hybrid model:
Phase 1 (India, 2–3 months): Intensive treatment initiation, sputum culture conversion confirmation, tolerance established, dosage optimised.
Phase 2 (home country, 3–4 months): Continuation phase with monthly teleconsultation with Indian pulmonologist, local laboratory monitoring (sputum culture, renal function, LFTs, ECG), and medication supply arrangements.
Arodya coordinates the handover with detailed treatment protocols, laboratory monitoring schedules, and direct contact with your Indian pulmonologist for home country physicians. This hybrid model keeps direct India costs down while maintaining specialist oversight.
TB and HIV Co-infection
Sub-Saharan Africa has the world's highest rates of TB-HIV co-infection. This complicates treatment significantly — drug interactions between antiretrovirals and TB drugs, immune reconstitution inflammatory syndrome (IRIS), and higher mortality risk.
India's specialist centres have extensive experience managing TB-HIV co-infection. Key considerations:
- Rifampicin and antiretrovirals: Rifampicin substantially reduces levels of most protease inhibitors and NNRTIs. Integrase inhibitors (dolutegravir, raltegravir) are preferred with rifampicin-based regimens.
- BPaL and antiretrovirals: Less interaction than rifampicin-based regimens. Bedaquiline and dolutegravir can be used together with careful QT monitoring.
- ART timing: In patients not already on ART, Indian guidelines recommend starting ART within 2 weeks of TB treatment for patients with CD4 below 50, and within 8 weeks for others.
What to Bring and Expect
When arriving for MDR-TB evaluation in India, bring:
- All previous sputum culture and DST results
- Previous chest X-rays and CT scans
- Complete medication history including all TB drugs previously taken and duration
- HIV status and current ART regimen if applicable
- GP and specialist letters summarising previous treatment
For Indian TB treatment, international patients should plan at least 4 to 6 weeks for the initial phase. Isolation requirements will depend on sputum status on arrival. Companions must follow hospital infection control protocols.
Ready to explore MDR-TB treatment in India? Share your case with Arodya's medical team — provide your DST results and treatment history for a personalised assessment and cost estimate.
For patients also considering other infectious disease treatments, see our guide to hepatitis B and C treatment in India. For understanding India's broader medical infrastructure, read about India's healthcare investment in 2026.
